FRESENIUS/ DE0005785604 /
23/01/2025 13:57:44 | Chg. +0.950 | Volume | Bid17:30:30 | Ask17:40:00 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
36.780EUR | +2.65% | 352 Turnover: 12,909.390 |
-Bid Size: - | -Ask Size: - | 20.71 bill.EUR | - | - |
GlobeNewswire
24/04/2024
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for ...
GlobeNewswire
23/04/2024
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track R...
GlobeNewswire
23/02/2024
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatm...
GlobeNewswire
04/09/2023
CIO Leadership: Generative AI and Visionary Leadership in the Enterprise Will Power the Discussion a...
GlobeNewswire
31/08/2023
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil